No involvement of the adenosine A2A receptor in tardive dyskinesia in Russian psychiatric inpatients from Siberia

Human Psychopharmacology

Volumn 27, Issue 3, 2012, Pages 334-337

  Ivanova, Svetlana A ^a   Al Hadithy, Asmar F Y ^b,c   Brazovskaya, Natalia ^e   Semke, Arkadiy ^a   Wilffert, Bob ^c   Fedorenko, Olga ^a   Brouwers, Jacobus R B J ^c   Loonen, Anton J M ^c,d  

^a MENTAL HEALTH RESEARCH INSTITUTE   (Russian Federation)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d GGZ Westelijk Noord Brabant   (Netherlands)

^e SIBERIAN STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

ADORA2A; dyskinesia, tardive; mechanism

Indexed keywords

ADENOSINE A2A RECEPTOR;

ADULT; ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GENE FREQUENCY; GENOTYPE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RUSSIAN FEDERATION; TARDIVE DYSKINESIA;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; DYSKINESIA, DRUG-INDUCED; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENOTYPE; HOSPITALIZATION; HUMANS; INPATIENTS; LOGISTIC MODELS; MALE; MIDDLE AGED; RECEPTOR, ADENOSINE A2A; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; SIBERIA;

EID: 84861152547     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2226     Document Type: Article

References (16)

1. Al Hadithy AF, Ivanova SA, Pechlivanoglou P, et al,. 2009. Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia. Prog Neuropsychopharmacol Biol Psychiatry 33 (3): 475-481.
2. Al Hadithy AF, Ivanova SA, Pechlivanoglou P, et al,. 2010. Missense polymorphisms in three oxidative-stress enzymes (GSTP1, SOD2, and GPX1) and dyskinesias in Russian psychiatric inpatients from Siberia. Hum Psychopharmacol 25 (1): 84-91.
3. Alsene K, Deckert J, Sand P, De Wit H,. 2003. Association between A2a receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 28 (9): 1694-1702. (Pubitemid 41070870)
4. Bishnoi M, Chopra K, Kulkarni SK,. 2006. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes. Eur J Pharmacol 552 (1-3): 55-66. (Pubitemid 44648080)
5. Bishnoi M, Chopra K, Kulkarni SK,. 2007. Theophylline, adenosine receptor antagonist prevents behavioral, biochemical and neurochemical changes associated with an animal model of tardive dyskinesia. Pharmacol Rep 59 (2): 181-191. (Pubitemid 46952408)
6. Ciruela F, Albergaria C, Soriano A, et al,. 2010. Adenosine receptors interacting proteins (ARIPs): behind the biology of adenosine signaling. Biochim Biophys Acta 1798 (1): 9-20.
7. Deckert J, Brenner M, Durany N, et al,. 2003. Up-regulation of striatal adenosine A(2A) receptors in schizophrenia. Neuroreport 14 (3): 313-316. (Pubitemid 36337921)
8. Dhaenens CM, Burnouf S, Simonin C, et al,. 2009. A genetic variation in the ADORA2A gene modifies age at onset in Huntington's disease. Neurobiol Dis 35 (3): 474-476.
9. Marsalek M,. 2000. Tardive drug-induced extrapyramidal syndromes. Pharmacopsychiatry 33 (Suppl 1): 14-33.
10. Rijcken CA, Monster TB, Brouwers JR, De Jong-van den Berg LT,. 2003. Chlorpromazine equivalents versus defined daily doses: how to compare antipsychotic drug doses? J Clin Psychopharmacol 23 (6): 657-659. (Pubitemid 37443196)
11. Rogers PJ, Hohoff C, Heatherley SV, et al,. 2010. Association of the anxiogenic and alerting effects of caffeine with ADORA2A and ADORA1 polymorphisms and habitual level of caffeine consumption. Neuropsychopharmacology 35 (9): 1973-1983.
12. Sebastiao AM, Ribeiro JA, 2009. Triggering neurotrophic factor actions through adenosine A2A receptor activation: implications for neuroprotection. Br J Pharmacol 158 (1): 15-22.
13. Shen W, Flajolet M, Greengard P, Surmeier DJ,. 2008. Dichotomous dopaminergic control of striatal synaptic plasticity. Science (New York, N.Y.) 321 (5890): 848-851.
14. Soares-Weiser K, Fernandez HH,. 2007. Tardive dyskinesia. Semin Neurol 27 (2): 159-169. (Pubitemid 46564477)
15. Taherzadeh-Fard E, Saft C, Wieczorek S, Epplen JT, Arning L,. 2010. Age at onset in Huntington's disease: replication study on the associations of ADORA2A, HAP1 and OGG1. Neurogenetics 11 (4): 435-439.
16. Zezula J, Freissmuth M,. 2008. The A(2A)-adenosine receptor: a GPCR with unique features? Br J Pharmacol 153 (Suppl 1): S184-S90.